MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

86.19
+5.41
+6.70%
Opening 11:21 04/06 EDT
OPEN
82.49
PREV CLOSE
80.78
HIGH
88.33
LOW
82.49
VOLUME
152.43K
TURNOVER
--
52 WEEK HIGH
97.56
52 WEEK LOW
37.01
MARKET CAP
4.60B
P/E (TTM)
-36.1338
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XLRN stock price target is 108.45 with a high estimate of 136.00 and a low estimate of 72.00.

EPS

XLRN News

More
  • Benzinga's Top Upgrades, Downgrades For April 6, 2020
  • Benzinga · 1h ago
  • Goldman Sachs Downgrades Acceleron Pharma to Sell, Announces $73 Price Target
  • Benzinga · 3h ago
  • Jefferies sees 51% upside in Jazz Pharma in premarket analyst action
  • Seeking Alpha - Article · 4h ago
  • Acceleron Receives Thumbs Up From Street On FDA Reblozyl Label Expansion
  • SmarterAnalyst · 5h ago

Industry

Biotechnology & Medical Research
+3.90%
Pharmaceuticals & Medical Research
+3.09%

Hot Stocks

Symbol
Price
%Change

About XLRN

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
More

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.